SION News
Archived Headlines
- Cystic fibrosis biotech Sionna Therapeutics sets terms for $150 million IPO 02/03/25
- US IPO Week Ahead: Cement carve-out leads the IPO calendar as more gear up to launch 01/31/25
- Sizable IPO filings reach a three-year high amid steady stream of deals 01/30/25
- US IPO Weekly Recap: Oil and gas well equipment provider Flowco debuts, while more sizable deals join the pipeline 01/17/25
- Cystic fibrosis biotech Sionna Therapeutics files for a $100 million IPO 01/17/25
Renaissance Capital's February IPO Market Update
Eighteen IPOs raised a combined $2.8 billion in February, well above the 10-year historical average (12 IPOs, $2.1B). Micro-caps dominated deal flow, but five issuers completed offerings of $100 million or more, led by SailPoint (SAIL), which raised $1.4...read more
Bigger Biotechs: IPO valuations have soared for drug developers over the past decade
New biotech issuers have doubled in size over the past decade.Last year, the average biotech IPO went public at a market cap of $644 million, compared to $318 million a decade earlier, for deals raising at least $20 million. The average wasn’t skewed by a ...read more
US IPO Weekly Recap: Cement and cystic fibrosis drugs lead a 6 IPO week
Two sizable companies and a handful of small Asian issuers listed in the US this past week.Titan America (TTAM), the US business unit of Titan Cement, priced slightly below the midpoint to raise $384 million at a $2.9 billion market cap. Operating primarily...read more
Cystic fibrosis biotech Sionna Therapeutics prices upsized IPO at $18, the high end of the range
Sionna Therapeutics, a Phase 1 biotech developing novel therapies for cystic fibrosis, raised $191 million by offering 10.6 million shares at $18, the high end of the range of $16 to $18. The company offered 1.8 million more shares than anticipated.Sionna is...read more